October 28, 2020
It’s no secret that real-world data is becoming a hot topic in the sphere of clinical trials and healthcare. A new study published by JMIR found that patients with multiple sclerosis were able to capture their symptoms via a tracking app called elevateMS. Researchers also found that engagement was highest among those who had a doctor’s referral.
“The elevateMS study app captured the real-world...
January 9, 2020
This morning patient social network MyHealthTeams revealed exclusively to MobiHealthNews that it is teaming up with EMD Serono to launch a new information resource for patients with multiple sclerosis (MS) who are pregnant or potentially becoming pregnant.
The new tool, called Family Planning Resource Center, will be available within MyMS team, which is part of MyHealthTeam’s social network...
September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.
The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.
Sanofi is currently...
May 28, 2019
Wearable sensor maker MC10 is teaming up with biopharma company AbbVie on a new set of multiple sclerosis (MS) clinical trials. The pair plan to use MC10’s FDA cleared wearable sensor technology, dubbed the BioStamp nPoint system, to help keep track of a patient’s physiological data and outcomes during the trials.
The flexible and stretchable electronic sensors landed FDA clearance last year to...
May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected.
Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS).
Pear Therapeutics has been developing Pear-...
June 12, 2018
Biogen has just launched a new app, called Aby, aimed at giving people living with multiple sclerosis (MS) accurate and reliable information about the condition and support.
The app is free and gives users articles, tips and inspirations about living with the condition. It also provides patients a personal journal, where they can create custom treatment reminders, track appointments, and record...
April 2, 2018
A study recently published in the BMJ’s Journal of Neurology, Neurosurgery, and Psychiatry found that a digital interactive therapy tool designed for multiple sclerosis patients, Gaia’s Elevida, was effective in reducing MS-related fatigue.
The randomized controlled trial included 275 participants with MS, and suggests that the intervention’s fatigue reduction effects could be sustained up to 12...
March 12, 2018
Duke University has launched a new Apple ResearchKit study, the MS Mosaic Study, aimed at using big data and patient insights to improve medical understanding of multiple sclerosis. Dr. Lee Hartsell, assistant professor of neurology at Duke University Medical Center, spoke about the new study -- and some of the challenges involved in launching it -- at the Digital and Personal Connect...
March 1, 2018
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear.
“We have been in discussions for many months now with the [Novartis Institutes for BioMedical Research] group at...
June 16, 2017
Bayer recently received FDA approval for a connected auto-injector for relapsing-remitting multiple sclerosis medication and companion app. The device is called the Betaconnect Electronic Autoinjector and the app, due out in July, is myBetaApp.
The Whippany, New Jersey-based pharma company didn't clear the app and device through the 510(k) medical device pathway; instead the agency approved a...